Sarepta Therapeutics (SRPT) Gross Margin (2017 - 2026)

Sarepta Therapeutics' Gross Margin history runs 10 years deep, the most recent figure standing at 72.83% for Q1 2026.

• In Q1 2026, Gross Margin rose 7600.0% year-over-year to 72.83%; the TTM figure through Mar 2026 stood at 56.26% (down 1870.0% YoY), while the FY2025 annual figure was 61.81%, down 2142.0% from the prior year.
• Gross Margin was 72.83% for Q1 2026 at Sarepta Therapeutics, up from 9.98% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 90.47% in Q4 2023 to a low of 53.37% in Q2 2023.
• Historically, Gross Margin has averaged 56.86% across 5 years, with a median of 80.37% in 2024.
• The sharpest annual moves came in 2023 and 2024: Gross Margin tumbled 13547 bps in 2023, then jumped 14109 bps in 2024.
• A 5-year view of Gross Margin shows it stood at 81.8% in 2022, then rose by 11 bps to 90.47% in 2023, then fell by 12 bps to 79.91% in 2024, then slumped by 88 bps to 9.98% in 2025, then jumped by 629 bps to 72.83% in 2026.
• The last three Gross Margin figures came in at 72.83% (Q1 2026), 9.98% (Q4 2025), and 62.25% (Q3 2025), per Business Quant data.